Which disease is distinguished by the presence of Reed-Sternberg cells? Classical Hodgkin lymphoma (cHL) is the disease defined by these cells. A Reed-Sternberg cell is a large, often binucleated B-cell-derived giant with prominent eosinophilic nucleoli, and finding it in the right inflammatory background is the diagnostic hallmark of cHL. Crucially, the cells are rare, sometimes fewer than 1% of the tumor mass, so the disease is identified by a minority population inside a majority of reactive immune cells.
The cellular mechanism behind the hallmark
Reed-Sternberg cells arise from germinal-center or post-germinal-center B lymphocytes that have crippled their own immunoglobulin genes. Most cHL cases show somatic hypermutation without functional immunoglobulin transcripts, so the cell cannot build a B-cell receptor. Normally that failure triggers apoptosis. The neoplastic clone escapes death through constitutive NF-κB signaling, often driven by Rel amplification on chromosome 2p or by inactivating mutations in TNFAIP3 (A20).
That survival program does two things. First, it lets a crippled B cell persist and proliferate. Second, it turns the cell into a cytokine factory, secreting IL-5, IL-6, IL-13, and CCL17/TARC. Those signals recruit eosinophils, histiocytes, and regulatory T cells that form the bulk of the tumor. The diagnostic giant cell is therefore a minority architect, not the bulk of the mass.
The classic diagnostic form is large and binucleate with mirror-image nuclei and a permissive nucleolus, the "owl-eye" appearance. A mononuclear variant, the Hodgkin cell, coexists. Immunophenotype matters as much as morphology: CD30 positive, CD15 positive in most cases, CD45 negative, and weak or absent B-cell markers such as CD20. The B-cell origin is proven by immunoglobulin gene rearrangement, not by surface staining.
Plain language: the tumor is a small number of broken B cells that talk the surrounding immune system into building a supportive crowd.
Quantified context and the diagnostic threshold
The rarity is the clinical problem. In many biopsies, neoplastic cells account for well under 5% of the cellular infiltrate, and classic teaching places the figure at roughly 1%. A pathologist scanning at low power sees a reactive-looking landscape of lymphocytes and eosinophils; the diagnostic cells hide inside it.
Epidemiology sharpens the picture. cHL accounts for roughly 10% of lymphomas overall, with an estimated 8,000 to 9,000 new US cases per year. It shows a bimodal age distribution, peaking in the third decade and again after age 55. Nodular sclerosis is the most common subtype in young adults, while mixed cellularity is more frequent in older patients and in resource-limited settings.
Outcome numbers give the diagnosis weight without implying individual prognosis. Modern multiagent chemotherapy plus response-adapted radiotherapy cures the large majority of limited-stage patients, with long-term overall survival historically reported above 80% in registry series. Exact current figures vary by stage, subtype, and era, so treat any single percentage as a population estimate, not a promise.
The counterintuitive protein marker is CD15. Despite cHL being a B-cell disease, the cells usually lack CD20 and instead express CD15, a marker more familiar on myeloid cells. A pathologist who demands strong CD20 positivity will miss the diagnosis entirely.
Timeline of how the finding is established
| Stage | Typical timing | What happens |
|---|---|---|
| Presentation | Weeks to months | Painless cervical or mediastinal lymphadenopathy, B symptoms in about a third |
| Biopsy | Days | Excisional node biopsy preferred over needle sampling |
| Morphology review | 1 to 3 days | Search for Reed-Sternberg and Hodgkin cells in the right background |
| Immunohistochemistry | 1 to 3 days | CD30, CD15, CD45, CD20, CD3, and PAX5 panel |
| Molecular or clonality testing | Days to 2 weeks | Immunoglobulin gene rearrangement when morphology is ambiguous |
| Staging | 1 to 2 weeks | PET-CT plus bone marrow assessment only in selected cases |
| Treatment start | Within weeks of diagnosis | Regimen chosen by stage, bulk, and risk features |
Timing figures are workflow approximations, not mandates. The ordering principle is stable: morphology first, phenotype to confirm, clonality only when the picture is equivocal.
Edge cases where the hallmark is absent or misleading
Reed-Sternberg-like cells are not exclusive to cHL. They appear in reactive states and in other lymphomas, which is why morphology alone can mislead.
| Entity | Reed-Sternberg-like cells | CD30 | CD15 | CD45 | Key discriminator |
|---|---|---|---|---|---|
| Classical Hodgkin lymphoma | Yes, diagnostic | Positive | Usually positive | Negative | PAX5 weak, CD20 negative |
| Nodular lymphocyte-predominant B-cell lymphoma | Rare, "popcorn" variants | Weak or negative | Negative | Positive | CD20 and CD45 positive |
| Anaplastic large-cell lymphoma | Yes, large pleomorphic cells | Strong positive | Usually negative | Positive | T-cell or null phenotype, ALK status |
| T-cell/histiocyte-rich large B-cell lymphoma | Occasional | Variable | Negative | Positive | CD20-positive large B cells |
| Infectious mononucleosis | Yes, immunoblastic mimics | Positive in activated cells | Variable | Positive | Clinical context, EBV serology |
| Melanoma and carcinoma | Rare mimics | Variable | Usually negative | Positive | Lineage markers such as S100 or keratins |
A second edge case is the "syncytial" variant of nodular sclerosis, where cells cluster and mimic other tumors. A third is early involvement in a small needle core, which samples the reactive background and misses the diagnostic cells entirely. That is why excisional biopsy remains the standard.
One professional caveat deserves emphasis: no single marker is required and sufficient. CD30 decorates activated lymphocytes throughout the biopsy, so a CD30 stain alone proves nothing. The diagnosis is a composite of architecture, morphology, and a coordinated panel.
Misconceptions and red-flag warnings
A common misconception holds that Reed-Sternberg cells are numerous and easy to spot. In reality, a dense eosinophil-rich infiltrate can contain a handful of diagnostic cells in an entire section.
Another misconception is that the finding alone confirms the disease. Pathologists call these cells "Reed-Sternberg-like" precisely because mimics exist, including in reactive follicles and in T-cell lymphomas.
A third misconception confuses cHL with nodular lymphocyte-predominant Hodgkin lymphoma. The latter has a different cell of origin, a different phenotype, and a different clinical course, and it is distinguished by the absence of classic Reed-Sternberg cells.
Seek urgent evaluation for a painless, enlarging lymph node persisting beyond 4 to 6 weeks. Red flag: unexplained fever above 38°C (100.4°F) recurring over days, or drenching night sweats. Red flag: unintentional weight loss exceeding 10% of body weight over 6 months. Red flag: new persistent itching, chest pressure, or breathlessness suggesting mediastinal bulk. Red flag: a needle-biopsy report of "atypical cells" without excisional tissue. Do not accept a lymphoma diagnosis from fine-needle aspiration alone.
Practical actions for patients and clinicians
For a patient, the actionable step is timing. A lymph node that persists beyond 4 to 6 weeks without an infectious explanation warrants examination, and one that is firm, painless, and growing warrants prompt referral.
For the clinician, the actionable step is sampling strategy. Excisional biopsy of an intact node yields architecture and enough tissue for a full immunophenotype panel; core needle biopsy carries a meaningful false-negative risk when the diagnostic cells are sparse. Fine-needle aspiration cannot establish cHL because it destroys architecture.
Communication matters after diagnosis. Ask whether the report documents CD30 and CD15 positivity with CD45 negativity, and whether PAX5 or immunoglobulin studies support B-cell lineage. Those details distinguish cHL from mimics with different treatments.
For treated patients, practical surveillance centers on PET-CT response assessment and reporting new B symptoms promptly. This article does not provide treatment regimens or dosing; those decisions belong to oncology teams.
Limitations of the hallmark and this evidence
The Reed-Sternberg cell is a defining feature, not a sufficient test. Interobserver variability in classifying Hodgkin variants is real, and discordant reviews occur even among expert hematopathologists. Access to a full immunohistochemistry panel varies by center, and resource-limited settings may rely on morphology plus a narrower panel.
Population-level survival figures are era-dependent and influenced by stage, age, and comorbidity, so they cannot predict an individual outcome. This article explains stable pathology and diagnostic logic; it deliberately omits current drug prices, approval status, and specific regimens because those change and were not verified here.
The final limitation is logical. A hallmark identifies a category, not a person. The presence of these cells supports a diagnosis of classical Hodgkin lymphoma only within the correct architectural and immunophenotypic context.
This article is general educational information, not a diagnosis, treatment plan, or medical advice. Only a qualified pathologist and treating physician can diagnose or manage lymphoma using your complete clinical picture. If you have an enlarging lymph node, persistent fever, drenching night sweats, or unexplained weight loss, contact a local clinician promptly; for immediate danger, use local emergency services.